The estimated Net Worth of William C Jr Bertrand is at least $1.57 Million dollars as of 16 January 2024. Mr. Bertrand owns over 23,589 units of Adaptimmune Therapeutics Plc stock worth over $21,817 and over the last 9 years he sold ADAP stock worth over $183,298. In addition, he makes $1,369,510 as Chief Operating Officer at Adaptimmune Therapeutics Plc.
William has made over 16 trades of the Adaptimmune Therapeutics Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 23,589 units of ADAP stock worth $16,512 on 16 January 2024.
The largest trade he's ever made was buying 207,000 units of Adaptimmune Therapeutics Plc stock on 14 December 2020 worth over $142,830. On average, William trades about 8,401 units every 84 days since 2015. As of 16 January 2024 he still owns at least 20,201 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Mr. Bertrand stock trades at the bottom of the page.
William C. Bertrand Jr., Esq., J.D. serves as Chief Operating Officer of the Company. Mr. Bertrand's prior experience includes a 12 year tenure at MedImmune, where he served as its first General Counsel and Chief Compliance Officer, along with holding a variety of operational and corporate strategy roles. He has also formerly served as Executive Vice President, General Counsel for Infinity Pharmaceuticals, Inc., and as Senior Vice President, Acting Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize the integration of the company's $14 billion acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx, Inc. (Nasdaq:ARDX). Mr. Bertrand received a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State University.
As the Chief Operating Officer of Adaptimmune Therapeutics Plc, the total compensation of William Bertrand at Adaptimmune Therapeutics Plc is $1,369,510. There are 2 executives at Adaptimmune Therapeutics Plc getting paid more, with James Noble having the highest compensation of $2,821,740.
William Bertrand is 55, he's been the Chief Operating Officer of Adaptimmune Therapeutics Plc since 2017. There are 7 older and 10 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
William's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include: